Autoimmune Disease Clinical Trial
Official title:
Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study
Verified date | December 12, 2006 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Autoimmune diseases may involve nearly any organ and are characterized by abnormal activation
or response of certain cells. Evidence suggests that farm work, exposure to silica from
farming activities and exposure to pesticides may contribute to the development of autoimmune
disease. Associations between autoimmune diseases and farming, however, have not been
extensively investigated, and exposure data in the currently available studies are extremely
limited.
One of the major challenges in conducting population-based research on autoimmune diseases is
case ascertainment. Self-report of previous diagnosis has proven to be unreliable. This
protocol outlines a strategy to confirm self-reported diagnoses of systemic autoimmune
diseases (rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and Sjogren
syndrome) within the Agricultural Health Study group (AHS; a group of licensed pesticide
applicators and spouses who completed a questionnaire). The confirmed cases will constitute a
refined case group to allow analyses of pesticides and other farming-related exposures as
possible risk factors for these diseases using data that have already been collected.
Subjects will be selected from participants in the AHS who reported one of the diseases being
studied. A short telephone interview will be conducted with participants, who will be
requested to provide written consent for review of information from medical records. To
confirm the self-diagnosis, participants' physicians will be contacted. Specific information
will be requested in the form of a checklist. Responses will be reviewed for evidence of
diagnosis and classified as confirmed, probable, physician-diagnosed, or unconfirmed.
Secondary objectives of this study are to:
- assess the correct interpretation of conflicting self-reports that are provided at two
different times.
- evaluate the usefulness of specific questions that could potentially be used in future
studies to validate self-reported cases of rheumatoid arthritis in men.
Status | Completed |
Enrollment | 700 |
Est. completion date | December 12, 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
- INCLUSION CRITERIA: Agricultural workers and their spouses. EXCLUSION CRITERIA: Children will not be included. There are no exclusions based on ethnicity or race. Participants who are unable to complete a telephone interview because of chronic illness (including cognitive impairment) or language or hearing difficulties will not be eligible. |
Country | Name | City | State |
---|---|---|---|
United States | Battelle Centers for Public Health Research and Evaluation | Durham | North Carolina |
United States | University of Iowa | Iowa City | Iowa |
United States | NIEHS, Research Triangle Park | Research Triangle Park | North Carolina |
Lead Sponsor | Collaborator |
---|---|
National Institute of Environmental Health Sciences (NIEHS) |
United States,
Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, Kazatchkine MD, Gilquin J, Viard JP. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000 Nov;85(11):4254-7. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT01934764 -
Identification of Correlations Between Reaction to Biotine and Autoimmune Diseases
|
N/A | |
Recruiting |
NCT01665196 -
18F-FDG PET/CT for IgG4-Related Disease
|
Early Phase 1 | |
Withdrawn |
NCT02948855 -
Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
|
||
Completed |
NCT01815996 -
Identify Clinical Conditions That Increase Circulating DNA Levels
|
||
Completed |
NCT02434458 -
Sudoscan in Patients With Autoimmune Disorders
|
N/A | |
Completed |
NCT02263703 -
Immunogenicity of HPV Vaccine in Immunosuppressed Children
|
Phase 3 | |
Completed |
NCT00013689 -
Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
|
Phase 1 | |
Completed |
NCT00340600 -
Continuation of Follow-up of DES-Exposed Cohorts
|
||
Not yet recruiting |
NCT05894707 -
Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02647866 -
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
|
Phase 2 | |
Active, not recruiting |
NCT00716066 -
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
|
Phase 2 | |
Completed |
NCT00351377 -
Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
|
Phase 3 | |
Completed |
NCT00114530 -
Scleroderma: Cyclophosphamide or Transplantation
|
Phase 2/Phase 3 | |
Completed |
NCT00001630 -
Treatment of Autoimmune Thrombocytopenia (AITP)
|
Phase 1 | |
Completed |
NCT00372177 -
The Use of Anti-CD4 Monoclonal Antibody (mAb)-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis
|
Phase 1/Phase 2 | |
Completed |
NCT00065390 -
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
|
Phase 1 | |
Completed |
NCT00001658 -
Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections
|
Phase 4 | |
Recruiting |
NCT03816345 -
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
|
Phase 1 | |
Completed |
NCT00001306 -
Steroid Therapy in Autoimmune Premature Ovarian Failure
|
N/A | |
Recruiting |
NCT03715699 -
Leflunomide Treatment for IgG4-RD
|
N/A |